Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
2023; Elsevier BV; Volume: 403; Issue: 10421 Linguagem: Inglês
10.1016/s0140-6736(23)02405-4
ISSN1474-547X
AutoresAna Oaknin, Laurence Gladieff, Jerónimo Martínez-García, Guillermo Villacampa, Munetaka Takekuma, Ugo De Giorgi, Kristina Lindemann, Linn Woelber, Nicoletta Colombo, Linda Duska, Alexandra Léary, Ana Godoy-Ortiz, Shin Nishio, Antoine Angelergues, María Jesús Rubio, Lorena Fariñas-Madrid, Satoshi Yamaguchi, Domenica Lorusso, Isabelle Ray‐Coquard, Luís Manso, Florence Joly, Jesús Alarcón, Philippe Follana, Ignacio Romero, Coriolan Lebreton, José Alejandro Pérez Fidalgo, Mayu Yunokawa, Hanna Dahlstrand, Véronique D’Hondt, Leslie M. Randall, Sophie Abadie‐Lacourtoisie, Claudia Andreetta, Nerea Anzizar, Daiseuke Aoki, Maria-Pilar Barretina-Ginesta, Marco Johannes Battista, Charlotte Bellier, Anne Gry Bentzen, Dominique Berton, Bertrand Billemont, Line Bjørge, Maria Bjurberg, Destin Black, Alessandra Bologna, Elena Ioana Braicu, Cláudia Casanova, Radoslav Chekerov, Annick Chevalier, Juan Cueva, Bastian Czogalla, Nicolas Delanoy, Dominik Denschlag, Oscar Derke, Michael Eichbaum, Takayuki Enomoto, Carmen Esteban, Michel Fabbro, Tanja Fehm, Annamaria Ferrero, Markus C. Fleisch, Anne Floquet, Antonio Frassoldati, Lydia Gaba, Angiolo Gadducci, Yolanda García García, Elena Geuna, Eva Guerra, Lars Hanker, Anne‐Claire Hardy‐Bessard, Philipp Harter, Kosei Hasegawa, Kristina Hellman, Ana Herrero, Felix Hilpert, Dionyssios Katsaros, Matthias Koegel, Anthoula Koliadi, Jean‐Emmanuel Kurtz, Bjoern Lampe, Andrea Alberto Lissoni, Alain Lortholary, Giorgia Mangili, Laura Mansi, Frederik Marmé, Cara Mathews, William Mina, Shinichiro Minobe, Katherine Moxley, Shoji Nagao, Ornella Nicoletto, Koji Nishino, Hiroshi Nishio, Shin Nishio, Ana Oaknin, Michaela Onstad, Beatriz Pardo, José Alejandro Pérez Fidalgo, Carmela Pisano, Andrés Poveda, Julia Caroline Radosa, Leslie M. Randall, Isabelle Ray‐Coquard, Andrés Redondo, Debra L. Richardson, Ignacio Romero, Graziana Ronzino, María Jesús Rubio, Frédèric Selle, Munetaka Takekuma, Nobuhiro Takeshima, Giulia Tasca, Krishnansu S. Tewari, Yukiharu Todo, Giorgio Valabrega, Pauline Wimberger, Linn Woelber, Satoshi Yamaguchi, Benoît You, Mayu Yunokawa,
Tópico(s)Colorectal and Anal Carcinomas
ResumoThe GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10-GEICO 68-C-JGOG1084-GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.
Referência(s)